285.00
+2.30%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BeOne Medicines
Its shares trade on Shanghai under the ticker 688235.SS. It has been listed since 3 February 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥36.84bn and net income of CN¥1.98bn. At that date it held total assets of CN¥55.18bn and shareholders' equity of CN¥29.23bn.
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company. The firm is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The firm has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. The company has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The firm has in-licensed the rights to distribute 13 approved medicines for the China market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Feb 2016
- Employees
- 9,212
- Website
- beigene.com ↗
Leadership
Pay as last reported
- Mr. John OylerCo-Founder, Executive Chairman of the Board, Chief Executive Officer, since 2010$16.7m
- Dr. Xiaobin WuPresident, Chief Operating Officer, General Manager - China
- Dr. Xiaodong WangCo-Founder, Non-Executive Director$4.3m
- MR. Aaron RosenbergChief Financial Officer, since 2024
- Mr. Chan LeeSenior Vice President, General Counsel
- Mr. Giancarlo BenelliSenior Vice President, Head of Europe
- Mr. Matthew ShaulisGeneral Manager, North America
- Dr. Lai WangGlobal Head of R&D
- Mr. Ranjeev KrishanaLead Non-Executive Independent Director$492,000
- Ms. Shalini SharpDirector
- Dr. Olivier BrandicourtIndependent Non-Executive Director
- Dr. Han DuganNon-Executive Independent Director$516,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 76
- Environment
- 75
- Social
- 99
- Governance
- 54
- Direct emissions (scope 1)
- 3,547 t
- Energy emissions (scope 2)
- 81,095 t
- Value chain emissions (scope 3)
- 662,688 t
- Women in the workforce
- 58.2%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in the Biotechnology sector with a focus on oncology medicines.
- Has three approved medicines including BRUKINSA, tislelizumab, and pamiparib.
- Owns global commercialization rights for oncology medicines in multiple regions.
Weaknesses
- Company is based in KY (Cayman Islands) which may pose regulatory challenges.
- No specific information on financial performance or market share provided.
- Relies on a limited number of approved medicines for revenue generation.
Opportunities
- Expanding market access for BRUKINSA in additional countries beyond current approvals.
- Potential to commercialize in-licensed medicines in China market.
- Growing global demand for oncology treatments and immunotherapies.
Threats
- Regulatory hurdles in different countries for medicine approvals.
- Competition from other biotechnology companies in oncology sector.
- Dependence on a few key products for revenue could lead to market volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.